Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 52

1.

[Immunosuppresive treatment in patients with lupus glomerulonephritis. Review of adverse events].

Miranda Limón JM, Mendoza L, Saavedra MA.

Reumatol Clin. 2006 Nov;2(6):313-21. doi: 10.1016/S1699-258X(06)73067-4. Epub 2008 Dec 10. Spanish.

2.

Lupus nephritis: current issues.

Mavragani CP, Moutsopoulos HM.

Ann Rheum Dis. 2003 Sep;62(9):795-8.

3.

Long-term outcome of diffuse proliferative lupus glomerulonephritis treated with cyclophosphamide.

Mok CC, Ying KY, Ng WL, Lee KW, To CH, Lau CS, Wong RW, Au TC.

Am J Med. 2006 Apr;119(4):355.e25-33.

PMID:
16564783
4.

Natural history and treatment of lupus nephritis.

Austin HA, Balow JE.

Semin Nephrol. 1999 Jan;19(1):2-11. Review.

PMID:
9952276
5.

[Development of antituberculous drugs: current status and future prospects].

Tomioka H, Namba K.

Kekkaku. 2006 Dec;81(12):753-74. Review. Japanese.

PMID:
17240921
6.

[Comparison of various cyclophosphamide treatment regimens on the course and outcome of lupus nephritis ].

Petrović R, Stojanović R, Novicić-Sasić D, Dimitrijević J, Pavlović S, Stojković D, Palić-Obradović D, Stevanović G, Prodanović S.

Srp Arh Celok Lek. 2002 Aug;130 Suppl 3:19-25. Serbian.

PMID:
12583309
7.

Therapeutic options for resistant lupus nephritis.

Mok CC.

Semin Arthritis Rheum. 2006 Oct;36(2):71-81. Epub 2006 Jul 12. Review.

PMID:
16884971
8.

A comparative study of two intensified pulse cyclophosphamide remission-inducing regimens for diffuse proliferative lupus nephritis: an Egyptian experience.

Sabry A, Abo-Zenah H, Medhat T, Sheashaa H, Mahmoud K, El-Huseini A.

Int Urol Nephrol. 2009;41(1):153-61. doi: 10.1007/s11255-007-9325-4. Epub 2008 Jan 24.

PMID:
18214709
9.

Treatment for lupus nephritis: a revisit.

Lai KN, Tang SC, Mok CC.

Nephrology (Carlton). 2005 Apr;10(2):180-8. Review.

PMID:
15877679
10.

Liposomal amphotericin B: a review of its use as empirical therapy in febrile neutropenia and in the treatment of invasive fungal infections.

Moen MD, Lyseng-Williamson KA, Scott LJ.

Drugs. 2009;69(3):361-92. doi: 10.2165/00003495-200969030-00010. Review.

PMID:
19275278
11.

The efficacy of intravenous pulse cyclophosphamide in the treatment of severe lupus nephritis in children.

Tangnararatchakit K, Tapaneya-Olarn C, Tapaneya-Olarn W.

J Med Assoc Thai. 1999 Nov;82 Suppl 1:S104-10.

PMID:
10730528
12.

Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide.

Houssiau FA, Vasconcelos C, D'Cruz D, Sebastiani GD, Garrido Ed Ede R, Danieli MG, Abramovicz D, Blockmans D, Mathieu A, Direskeneli H, Galeazzi M, Gül A, Levy Y, Petera P, Popovic R, Petrovic R, Sinico RA, Cattaneo R, Font J, Depresseux G, Cosyns JP, Cervera R.

Arthritis Rheum. 2002 Aug;46(8):2121-31.

13.

Treatment of diffuse proliferative lupus glomerulonephritis: a comparison of two cyclophosphamide-containing regimens.

Mok CC, Ho CT, Siu YP, Chan KW, Kwan TH, Lau CS, Wong RW, Au TC.

Am J Kidney Dis. 2001 Aug;38(2):256-64.

PMID:
11479150
14.

Substitution of methotrexate for cyclophosphamide in Wegener granulomatosis: a 12-year single-practice experience.

Villa-Forte A, Clark TM, Gomes M, Carey J, Mascha E, Karafa MT, Roberson G, Langford CA, Hoffman GS.

Medicine (Baltimore). 2007 Sep;86(5):269-77.

15.

[Intravenous cyclophosphamide in lupus nephritis: twenty years reducing dose].

Frutos MA, Martín Gómez A, de Ramón E, Camps MT, Valera A, García I, Fernández Nebro A.

Nefrologia. 2007;27(1):12-22. Spanish.

16.

Effect of lower dose intravenous cyclophosphamide on remission induction in Korean patients with lupus nephritis.

Seong SS, Choi CB, Yun HR, Kim YJ, Sung YK, Bae SC.

Rheumatol Int. 2008 Mar;28(5):453-8. Epub 2007 Oct 9.

PMID:
17924111
17.

Longterm followup of childhood lupus nephritis.

Hagelberg S, Lee Y, Bargman J, Mah G, Schneider R, Laskin C, Eddy A, Gladman D, Urowitz M, Hebert D, Silverman E.

J Rheumatol. 2002 Dec;29(12):2635-42.

PMID:
12465165
18.

Treatment with cyclophosphamide delays the progression of chronic lesions more effectively than does treatment with azathioprine plus methylprednisolone in patients with proliferative lupus nephritis.

Grootscholten C, Bajema IM, Florquin S, Steenbergen EJ, Peutz-Kootstra CJ, Goldschmeding R, Bijl M, Hagen EC, Van Houwelingen HC, Derksen RH, Berden JH; Dutch Working Party on Systemic Lupus Erythematosus..

Arthritis Rheum. 2007 Mar;56(3):924-37.

19.

Histopathologic and clinical outcome of rituximab treatment in patients with cyclophosphamide-resistant proliferative lupus nephritis.

Gunnarsson I, Sundelin B, Jónsdóttir T, Jacobson SH, Henriksson EW, van Vollenhoven RF.

Arthritis Rheum. 2007 Apr;56(4):1263-72.

20.

Treatment of lupus nephritis.

Hejaili FF, Moist LM, Clark WF.

Drugs. 2003;63(3):257-74. Review.

PMID:
12534331

Supplemental Content

Support Center